Kiran Mazumdar-Shaw

About

The only concession that Kiran Mazumdar-Shaw makes to her years is that she is now the executive chairperson of Biocon and Biocon Biologics and non-executive chairperson for Syngene International Ltd. Having started in 1978 as an industrial enzymes firm, Biocon has had many firsts in the Indian bio pharma sector, including fermentation-based small molecules, human insulin and insulin analogs, biosimilars for key antibody drugs, and novel therapies or high-end contract research services. Group company Biocon Biologics provides affordable access to life-saving biologic treatments and has launched eight biosimilars globally, including Ogivri, Fulphila and Abevmy for cancer; Semglee and Insugen for diabetes; and Hulio and Nepexto for autoimmune diseases. Biocon Biologics is currently ranked among the Top 5 biosimilars companies globally. Its generics business, which has a robust portfolio of 50-plus APIs and 60-plus generic formulations, caters to over 750 pharma companies. Syngene, on the other hand, has emerged as a contract research, development and manufacturing organisation (CRDMO), delivering research and ensuring robust data security and high-quality manufacturing at speed to improve time-to-market and lower the cost of innovation for 400-plus clients worldwide. Shaw also runs the Biocon Foundation, and the 1,400-bed Mazumdar Shaw Medical Centre, in collaboration with Devi Shetty.